A Study on the Clinical Features of Metastatic Castration-Resistant Prostate Cancer Using PSMA-PET and FDG-PET

A Study on the Clinical Features of Metastatic Castration-Resistant Prostate Cancer Using PSMA-PET and FDG-PET - Analysis of Prostate Cancer Using PSMA-PET and FDG-PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060979

Enrollment

100

Registered

2026-03-19

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

FDG-PET/CT

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with metastatic castration-resistant prostate cancer undergoing PSMA-PET/CT imaging to aid in determining eligibility for radioligand therapy

Exclusion criteria

Exclusion criteria: Individuals who declined to participate in this study

Design outcomes

Primary

Measure	Time frame
To evaluate the association between PSMA expression and tumor characteristics in patients with metastatic castration-resistant prostate cancer using a combination of 68Ga-PSMA-PET/CT and FDG-PET/CT.	—

Countries

Japan

Contacts

Public ContactKoji Hatano

The University of Osaka Graduate School of Medicine Urology

koj.hatan@gmail.com06-6879-3531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026